AlphaVax Overview

  • Year Founded
  • 1997

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 9

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $20M

AlphaVax General Information

Description

Developer of vaccines for cancer immunotherapy intended for anti-infective and anti-cancer vaccines. The company engages a proprietary RNA replicon vector platform derived from attenuated strains of the alphavirus to treat diseases such as influenza, cytomegalovirus, HIV, prostate cancer, and breast cancer, among others, enabling healthcare providers to have access to novel therapies to better treat diseases in patients.

Contact Information

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 2 Triangle Drive
  • Po Box 110307, Research Triangle Park
  • Durham, NC 27709-0307
  • United States
+1 (800)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
Vertical(s)
Corporate Office
  • 2 Triangle Drive
  • Po Box 110307, Research Triangle Park
  • Durham, NC 27709-0307
  • United States
+1 (800)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AlphaVax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 29-Dec-2008 $20M Completed Clinical Trials - Phase 2
9. Grant 10-Jul-2007 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series E) 05-Feb-2007 Completed Clinical Trials - Phase 2
7. Grant 19-Oct-2005 Completed Clinical Trials - Phase 2
6. Grant 17-Nov-2004 Completed Clinical Trials - Phase 2
5. Later Stage VC 06-Jan-2004 Completed Clinical Trials - Phase 2
4. Grant 21-Oct-2003 Completed Clinical Trials - Phase 2
3. Later Stage VC (Series C) 03-Apr-2002 Completed Clinical Trials - Phase 2
2. Accelerator/Incubator 01-Jan-2002 $8.2M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series B) 28-Feb-2001 $8.2M $8.2M Completed Clinical Trials - Phase 2
To view AlphaVax’s complete valuation and funding history, request access »

AlphaVax Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of vaccines for cancer immunotherapy intended for anti-infective and anti-cancer vaccines. The company engages
Drug Discovery
Durham, NC
9 As of 2022

Philadelphia, PA
 

Beijing, China
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AlphaVax Competitors (73)

One of AlphaVax’s 73 competitors is Aro Biotherapeutics, a Venture Capital-Backed company based in Philadelphia, PA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Mabworks Biotech Venture Capital-Backed Beijing, China
Inovio Pharmaceuticals Corporation Plymouth Meeting, PA
Symphogen Formerly VC-backed Ballerup, Denmark
Gracell Formerly VC-backed Shanghai, China
You’re viewing 5 of 73 competitors. Get the full list »

AlphaVax Patents

AlphaVax Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2010234362-A1 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
AU-2010234362-B2 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
AU-2015249175-A1 Alphavirus replicon particles expressing trp2 Inactive 08-Apr-2009
AU-2017276161-A1 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
AU-2017276161-B2 Alphavirus replicon particles expressing trp2 Active 08-Apr-2009
To view AlphaVax’s complete patent history, request access »

AlphaVax Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

AlphaVax Former Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institute Of Allergy and Infectious Diseases Government
National Institute for Allergy and Infectious Disease Government
Springboard Enterprises Accelerator/Incubator
To view AlphaVax’s complete investors history, request access »

AlphaVax FAQs

  • When was AlphaVax founded?

    AlphaVax was founded in 1997.

  • Where is AlphaVax headquartered?

    AlphaVax is headquartered in Durham, NC.

  • What is the size of AlphaVax?

    AlphaVax has 9 total employees.

  • What industry is AlphaVax in?

    AlphaVax’s primary industry is Drug Discovery.

  • Is AlphaVax a private or public company?

    AlphaVax is a Private company.

  • What is the current valuation of AlphaVax?

    The current valuation of AlphaVax is .

  • What is AlphaVax’s current revenue?

    The current revenue for AlphaVax is .

  • How much funding has AlphaVax raised over time?

    AlphaVax has raised $32.8M.

  • Who are AlphaVax’s investors?

    National Institute Of Allergy and Infectious Diseases, National Institute for Allergy and Infectious Disease, and Springboard Enterprises have invested in AlphaVax.

  • Who are AlphaVax’s competitors?

    Aro Biotherapeutics, Mabworks Biotech, Inovio Pharmaceuticals, Symphogen, and Gracell are some of the 73 competitors of AlphaVax.

  • When was AlphaVax acquired?

    AlphaVax was acquired on 29-Dec-2008.

  • Who acquired AlphaVax?

    AlphaVax was acquired by Novartis.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process